Pharmacokinetics, Pharmacodynamics, and Safety of Entospletinib, a Novel pSYK Inhibitor, Following Single and Multiple Oral Dosing in Healthy Volunteers

Published 2016 View Full Article

Authors

Keywords

Multiple Dose, Mantle Cell Lymphoma, Spleen Tyrosine Kinase, Refractory Chronic Lymphocytic Leukemia, Dilution Quality Control Sample

Journal

CLINICAL DRUG INVESTIGATION

Volume 37, Issue 2, Pages 195-205

Publisher

Springer Nature

Online

2016-10-26

DOI

10.1007/s40261-016-0476-x

References

View 5 related references

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation